Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6IYAT)

• Drug Name: PMID28270010-Compound-Figure21-b Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Brain metastases	2D50	Patented	[1]

• Cross-matching ID:
  PubChem CID: 71731823
  ChEBI ID: CHEBI:143117
  CAS Number: CAS 1454846-35-5
  TTD Drug ID: DM6IYAT
  ACDINA Drug ID: D01222

Molecule-Related Drug Atlas

Drug(s) Targeting ALK tyrosine kinase receptor (ALK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[2]
Lorlatinib	DMICDLV	Non-small-cell lung cancer	2C25.Y	Approved	[3]
Entrectinib	DMMPTLH	Non-small cell lung cancer	2C25	Approved	[4]
Brigatinib	DM7W94S	Anaplastic large cell lymphoma	2A90.A	Approved	[5]
Ceritinib	DMB920Z	Non-small-cell lung cancer	2C25.Y	Approved	[6]
Alectinib	DMP1I6Y	Lung cancer	2C25.0	Approved	[7]
Ensartinib	DMIKDCQ	Non-small-cell lung cancer	2C25.Y	Phase 3	[8]
PF-06463922	DMKM7EW	Non-small-cell lung cancer	2C25.Y	Phase 2	[9]
AP26113	DMYBQEF	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
TPX-0005	DM9FB2T	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[8]

Drug(s) Targeting Proto-oncogene c-Ros (ROS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[2]
Lorlatinib	DMICDLV	Non-small-cell lung cancer	2C25.Y	Approved	[3]
Entrectinib	DMMPTLH	Non-small cell lung cancer	2C25	Approved	[4]
AB-106	DMEW62S	Non-small cell lung cancer	2C25	Phase 2	[11]
TPX-0005	DM9FB2T	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[8]
DS-6051	DM0RD4F	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
Carboxamide derivative 4	DMU5GKC	N. A.	N. A.	Patented	[13]
Imidazo[1,2-b]pyridazine derivative 2	DM1JYNW	Solid tumour/cancer	2A00-2F9Z	Patented	[1]
Imidazo[1,2-b]pyridazine derivative 3	DMPDTG0	Solid tumour/cancer	2A00-2F9Z	Patented	[1]
Imidazo[1,2-b]pyridazine derivative 1	DMULTAI	Solid tumour/cancer	2A00-2F9Z	Patented	[1]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ALK tyrosine kinase receptor (ALK)	TTPMQSO	ALK_HUMAN	Inhibitor	[1]
Proto-oncogene c-Ros (ROS1)	TTSZ6Y3	ROS1_HUMAN	Inhibitor	[1]

References

• [1] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7397).
• [7] CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011 May 17;19(5):679-90.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015 Jul 13;28(1):70-81.
• [10] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [11] Clinical pipeline report, company report or official report of AnHeart Therapeutics.
• [12] National Cancer Institute Drug Dictionary (drug id 766123).
• [13] RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.